Equities researchers at StockNews.com started coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) in a research report issued to clients and investors on Sunday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Stock Performance
NASDAQ TTNP opened at $3.81 on Friday. The company’s 50-day moving average price is $4.81 and its 200-day moving average price is $5.70. Titan Pharmaceuticals has a 12 month low of $3.57 and a 12 month high of $14.80.
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last posted its quarterly earnings results on Thursday, August 15th. The specialty pharmaceutical company reported ($2.29) EPS for the quarter.
Titan Pharmaceuticals Company Profile
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
Further Reading
- Five stocks we like better than Titan Pharmaceuticals
- 3 Healthcare Dividend Stocks to Buy
- ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
- What is the Nikkei 225 index?
- Freeport-McMoRan, Copper Demand Short-Term Pain, Long-Term Gain
- How to invest in marijuana stocks in 7 steps
- Time to Load Up on Home Builders?
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
